Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells - PubMed (original) (raw)
Clinical Trial
. 2006 Dec;12(12):1397-402.
doi: 10.1038/nm1504. Epub 2006 Nov 19.
Graziella Pellegrini, Stefano Ferrari, Francesca Di Nunzio, Enzo Di Iorio, Alessandra Recchia, Giulietta Maruggi, Giuliana Ferrari, Elena Provasi, Chiara Bonini, Sergio Capurro, Andrea Conti, Cristina Magnoni, Alberto Giannetti, Michele De Luca
Affiliations
- PMID: 17115047
- DOI: 10.1038/nm1504
Clinical Trial
Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells
Fulvio Mavilio et al. Nat Med. 2006 Dec.
Abstract
The continuous renewal of human epidermis is sustained by stem cells contained in the epidermal basal layer and in hair follicles. Cultured keratinocyte stem cells, known as holoclones, generate sheets of epithelium used to restore severe skin, mucosal and corneal defects. Mutations in genes encoding the basement membrane component laminin 5 (LAM5) cause junctional epidermolysis bullosa (JEB), a devastating and often fatal skin adhesion disorder. Epidermal stem cells from an adult patient affected by LAM5-beta3-deficient JEB were transduced with a retroviral vector expressing LAMB3 cDNA (encoding LAM5-beta3), and used to prepare genetically corrected cultured epidermal grafts. Nine grafts were transplanted onto surgically prepared regions of the patient's legs. Engraftment was complete after 8 d. Synthesis and proper assembly of normal levels of functional LAM5 were observed, together with the development of a firmly adherent epidermis that remained stable for the duration of the follow-up (1 year) in the absence of blisters, infections, inflammation or immune response. Retroviral integration site analysis indicated that the regenerated epidermis is maintained by a defined repertoire of transduced stem cells. These data show that ex vivo gene therapy of JEB is feasible and leads to full functional correction of the disease.
Comment in
- Skin regeneration with insights.
[No authors listed] [No authors listed] Nature. 2017 Nov 8;551(7679):141. doi: 10.1038/551141a. Nature. 2017. PMID: 29120439 No abstract available.
Similar articles
- Toward epidermal stem cell-mediated ex vivo gene therapy of junctional epidermolysis bullosa.
Dellambra E, Pellegrini G, Guerra L, Ferrari G, Zambruno G, Mavilio F, De Luca M. Dellambra E, et al. Hum Gene Ther. 2000 Nov 1;11(16):2283-7. doi: 10.1089/104303400750035825. Hum Gene Ther. 2000. PMID: 11084687 Review. - Corrective transduction of human epidermal stem cells in laminin-5-dependent junctional epidermolysis bullosa.
Dellambra E, Vailly J, Pellegrini G, Bondanza S, Golisano O, Macchia C, Zambruno G, Meneguzzi G, De Luca M. Dellambra E, et al. Hum Gene Ther. 1998 Jun 10;9(9):1359-70. doi: 10.1089/hum.1998.9.9-1359. Hum Gene Ther. 1998. PMID: 9650620 - Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors.
Di Nunzio F, Maruggi G, Ferrari S, Di Iorio E, Poletti V, Garcia M, Del Rio M, De Luca M, Larcher F, Pellegrini G, Mavilio F. Di Nunzio F, et al. Mol Ther. 2008 Dec;16(12):1977-85. doi: 10.1038/mt.2008.204. Epub 2008 Sep 23. Mol Ther. 2008. PMID: 18813277 - CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient.
Benati D, Miselli F, Cocchiarella F, Patrizi C, Carretero M, Baldassarri S, Ammendola V, Has C, Colloca S, Del Rio M, Larcher F, Recchia A. Benati D, et al. Mol Ther. 2018 Nov 7;26(11):2592-2603. doi: 10.1016/j.ymthe.2018.07.024. Epub 2018 Aug 4. Mol Ther. 2018. PMID: 30122422 Free PMC article. - Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.
Keith AR, Twaroski K, Ebens CL, Tolar J. Keith AR, et al. Expert Opin Biol Ther. 2020 Aug;20(8):911-923. doi: 10.1080/14712598.2020.1740678. Epub 2020 Mar 20. Expert Opin Biol Ther. 2020. PMID: 32178539 Free PMC article. Review.
Cited by
- Biochemical characterization of the feedforward loop between CDK1 and FOXM1 in epidermal stem cells.
Polito MP, Romaldini A, Tagliazucchi L, Marini G, Radice F, Gozza GA, Bergamini G, Costi MP, Enzo E. Polito MP, et al. Biol Direct. 2024 Oct 13;19(1):91. doi: 10.1186/s13062-024-00540-8. Biol Direct. 2024. PMID: 39396994 Free PMC article. - Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa.
Levian B, Hou Y, Tang X, Bainvoll L, Zheng K, Badarinarayana V, Aghamohammadzadeh S, Chen M. Levian B, et al. Mol Ther Nucleic Acids. 2024 Sep 10;35(4):102334. doi: 10.1016/j.omtn.2024.102334. eCollection 2024 Dec 10. Mol Ther Nucleic Acids. 2024. PMID: 39391765 Free PMC article. - A cellular disease model toward gene therapy of _TGM1_-dependent lamellar ichthyosis.
Sercia L, Romano O, Marini G, Enzo E, Forcato M, De Rosa L, De Luca M. Sercia L, et al. Mol Ther Methods Clin Dev. 2024 Jul 31;32(3):101311. doi: 10.1016/j.omtm.2024.101311. eCollection 2024 Sep 12. Mol Ther Methods Clin Dev. 2024. PMID: 39234443 Free PMC article. - Skin Development and Disease: A Molecular Perspective.
Dermitzakis I, Chatzi D, Kyriakoudi SA, Evangelidis N, Vakirlis E, Meditskou S, Theotokis P, Manthou ME. Dermitzakis I, et al. Curr Issues Mol Biol. 2024 Jul 30;46(8):8239-8267. doi: 10.3390/cimb46080487. Curr Issues Mol Biol. 2024. PMID: 39194704 Free PMC article. Review. - Epidermal stem cells: skin surveillance and clinical perspective.
Tang X, Wang J, Chen J, Liu W, Qiao P, Quan H, Li Z, Dang E, Wang G, Shao S. Tang X, et al. J Transl Med. 2024 Aug 22;22(1):779. doi: 10.1186/s12967-024-05600-1. J Transl Med. 2024. PMID: 39169334 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical